Picture of Ergomed logo

ERGO Ergomed News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeMid CapHigh Flyer

REG - Ergomed plc - Block Listing Six Monthly Return





 




RNS Number : 7694L
Ergomed plc
02 January 2019
 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 2 January 2019

 

Name of applicant:

Ergomed plc

Name of scheme:

Ergomed plc Long Term Incentive Plan

Period of return:

From:

2 July 2018

To:

31 December 2018

Balance of unallotted securities under scheme(s) from previous return:

1,800,000 (original admission)

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

nil

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

55,000

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

1,745,000

Number and class of securities originally admitted and the date of admission

1,800,000 ordinary shares of 1p each - 2 July 2018

Total number of securities in issue at the end of the period

45,016,438 ordinary shares of 1p each

 

Name of contact:

Nick Blech - Deputy CFO

Telephone number of contact:

+44 (0)7768 547372

 

 Enquiries:

Ergomed plc

Tel: +44 (0) 1483 503205

Stephen Stamp (Chief Executive Officer)


Stuart Jackson (Chief Financial Officer)

 




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)


James Black (Broker)

 


Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Matthew Neal / Olivia Manser

 

ergomed@consilium-comms.com



MC-Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke


 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRFEWFWAFASEEE

Recent news on Ergomed

See all news